logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Metastatic NSCLC: no clear benefit with chemo add-on to durvalumab+tremelimumab

Addition of platinum-based regimen yielded no OS improvement.